Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2015

01-09-2015

Applying evidence from economic evaluations to translate cancer survivorship research into care

Authors: Janet S. de Moor, Catherine M. Alfano, Nancy Breen, Erin E. Kent, Julia Rowland

Published in: Journal of Cancer Survivorship | Issue 3/2015

Login to get access

Abstract

Purpose

This paper summarizes recommendations stemming from the meeting, Applying Evidence from Economic Evaluations to Translate Cancer Survivorship Research into Care, hosted by the National Cancer Institute.

Methods

The meeting convened funded investigators, experts in cancer control, survivorship, health economics, and team science to identify the economic and health services data needed to facilitate the dissemination of cancer survivorship interventions into care and how survivorship and health economic investigators can successfully collaborate together and with other stakeholders.

Results

Recommendations from the meeting are as follows. First, investigators must engage key stakeholders early in the planning process to understand the outcomes and cost domains on which they base decisions. Second, evaluations of intervention efficacy and value should be conducted using standardized and comparable measures and analytic approaches to enable comparisons across studies. Finally, a health economist should be included during the planning phase of the study so that the economic evaluation is pursued in concert with the survivorship intervention.

Conclusions

Economic analyses, from the perspective of key stakeholders, must be incorporated into survivorship intervention research. The results from these analyses should be disseminated in a manner that is transparent, accessible, and comparable across studies.

Implications for Cancer Survivors

To optimize cancer survivors’ health and quality of life, it is essential deliver high-quality and high-value care. Incorporating economic analyses into survivorship intervention research can inform the translation of effective interventions into practice.
Footnotes
1
Opportunity cost: the money or other benefits lost when pursuing a particular course of action instead of a mutually exclusive alternative (opportunity cost. Dictionary.com. Dictionary.com Unabridged. Random House, Inc. http://​dictionary.​reference.​com/​browse/​opportunitycost) (accessed: November 10, 2014).
 
Literature
1.
go back to reference American Cancer Society. Cancer treatment survivorship facts figures, 2014–2015. Atlanta: American Cancer Society; 2014. American Cancer Society. Cancer treatment survivorship facts figures, 2014–2015. Atlanta: American Cancer Society; 2014.
2.
go back to reference Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006;12(5):432–43.CrossRefPubMed Alfano CM, Rowland JH. Recovery issues in cancer survivorship: a new challenge for supportive care. Cancer J. 2006;12(5):432–43.CrossRefPubMed
5.
go back to reference Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2108–17. doi:10.1158/1055-9965.EPI-12-0740.PubMedCentralCrossRefPubMed Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2108–17. doi:10.​1158/​1055-9965.​EPI-12-0740.PubMedCentralCrossRefPubMed
8.
go back to reference Johannsen M, Farver I, Beck N, Zachariae R. The efficacy of psychosocial intervention for pain in breast cancer patients and survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138(3):675–90. doi:10.1007/s10549-013-2503-4.CrossRefPubMed Johannsen M, Farver I, Beck N, Zachariae R. The efficacy of psychosocial intervention for pain in breast cancer patients and survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138(3):675–90. doi:10.​1007/​s10549-013-2503-4.CrossRefPubMed
9.
11.
go back to reference Glasgow RE, Klesges LM, Dzewaltowski DA, Bull SS, Estabrooks P. The future of health behavior change research: what is needed to improve translation of research into health promotion practice? Ann Behav Med. 2004;27(1):3–12. doi:10.1207/s15324796abm2701_2.CrossRefPubMed Glasgow RE, Klesges LM, Dzewaltowski DA, Bull SS, Estabrooks P. The future of health behavior change research: what is needed to improve translation of research into health promotion practice? Ann Behav Med. 2004;27(1):3–12. doi:10.​1207/​s15324796abm2701​_​2.CrossRefPubMed
14.
15.
go back to reference AA1000 Stakeholder Engagement Standard 2011: Final Exposure Draft. London, UK: AccountAbility 2011. AA1000 Stakeholder Engagement Standard 2011: Final Exposure Draft. London, UK: AccountAbility 2011.
17.
go back to reference Hartzler A, McCarty CA, Rasmussen LV, Williams MS, Brilliant M, Bowton EA, et al. Stakeholder engagement: a key component of integrating genomic information into electronic health records. Genet Med: Off J Am Coll Med Genet. 2013;15(10):792–801. doi:10.1038/gim.2013.127.CrossRef Hartzler A, McCarty CA, Rasmussen LV, Williams MS, Brilliant M, Bowton EA, et al. Stakeholder engagement: a key component of integrating genomic information into electronic health records. Genet Med: Off J Am Coll Med Genet. 2013;15(10):792–801. doi:10.​1038/​gim.​2013.​127.CrossRef
20.
go back to reference EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef EuroQol G. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
21.
go back to reference Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
23.
go back to reference Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am. 2000;14(4):925–38.CrossRefPubMed Ramsey SD, McIntosh M, Etzioni R, Urban N. Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am. 2000;14(4):925–38.CrossRefPubMed
25.
go back to reference Lomas J, Culyer T, McCutcheon C, McAuley L, Law S. Conceptualizing and combining evidence for health system guidance. Ott, Ont: Cana Health Services Res Found. 2005 May;2005. Lomas J, Culyer T, McCutcheon C, McAuley L, Law S. Conceptualizing and combining evidence for health system guidance. Ott, Ont: Cana Health Services Res Found. 2005 May;2005.
26.
go back to reference Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel Cost-Eff Health Med JAMA. 1996;276(14):1172–7. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel Cost-Eff Health Med JAMA. 1996;276(14):1172–7.
27.
go back to reference Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8.CrossRefPubMed Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8.CrossRefPubMed
31.
go back to reference Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med: Off J Am Coll Med Genet. 2007;9(10):665–74. doi:10.1097/GIM.0b013e31815699d0.CrossRef Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med: Off J Am Coll Med Genet. 2007;9(10):665–74. doi:10.​1097/​GIM.​0b013e31815699d0​.CrossRef
33.
go back to reference Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, McCrat AT, editors. Yearbook of medical informatics 2000: patient-centered systems. Stuttgart: Schattauer Verlagsgesellschaft mbH; 2000. p. 60–75. Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, McCrat AT, editors. Yearbook of medical informatics 2000: patient-centered systems. Stuttgart: Schattauer Verlagsgesellschaft mbH; 2000. p. 60–75.
34.
35.
go back to reference Helfand M. Incorporating information about cost-effectiveness into evidence-based decision-making: the evidence-based practice center (EPC) model. Med Care. 2005;43(7 Suppl):33–43.PubMed Helfand M. Incorporating information about cost-effectiveness into evidence-based decision-making: the evidence-based practice center (EPC) model. Med Care. 2005;43(7 Suppl):33–43.PubMed
36.
go back to reference Russell LB. The methodologic partnership of effectiveness reviews and cost-effectiveness analysis. Am J Prev Med. 2001;20(3 Suppl):10–2.CrossRefPubMed Russell LB. The methodologic partnership of effectiveness reviews and cost-effectiveness analysis. Am J Prev Med. 2001;20(3 Suppl):10–2.CrossRefPubMed
37.
go back to reference Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p 176–213. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis In: Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p 176–213.
Metadata
Title
Applying evidence from economic evaluations to translate cancer survivorship research into care
Authors
Janet S. de Moor
Catherine M. Alfano
Nancy Breen
Erin E. Kent
Julia Rowland
Publication date
01-09-2015
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2015
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0433-3

Other articles of this Issue 3/2015

Journal of Cancer Survivorship 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine